ClinicalTrials.gg

Program

silodosin

Also written as “Silodosin”, “KSO-0400” and “Silodosin Capsules”.

Its studies are mostly in Prostatic Hyperplasia · Nocturia · Lower Urinary Tract Symptoms · Ureteral Calculi · Ureterolithiasis, led by 6 companies.

Furthest: phase 4, since Sep 14, 200517 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie60 open or runningphase 3since Sep 14, 2005Sep 14, 2005none ahead
JW Pharmaceutical50 open or runningphase 4since Oct 25, 2010Oct 25, 2010none ahead
Kissei Pharmaceutical20 open or runningphase 2since Oct 15, 2010Oct 15, 2010none ahead
RECORDATI GROUP20 open or runningphase 4since Dec 21, 2012Aug 2, 2006none ahead
Shanghai Huilun Pharmaceutical10 open or runningphase 4since Aug 14, 2025Aug 14, 2025none ahead
Xintian Pharmaceutical10 open or runningphase 4since Sep 19, 2022Sep 19, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2005First studies: 3 phase 3 studies in Prostatic HyperplasiaNew to AbbVieAbbVie · NCT00224133, NCT00224120, NCT00224107
  2. Aug 2, 2006RECORDATI GROUP's first study: phase 3 study in Prostatic HyperplasiaNew to RECORDATI GROUPRECORDATI GROUP · NCT00359905 · 1,228 enrolled · United Kingdom
  3. Aug 21, 2008Phase 2 study in ProstatitisAbbVie · NCT00740779 · 153 enrolled · United States
  4. Nov 17, 2008Phase 2 study in NocturiaAbbVie · NCT00793819 · 215 enrolled · United States
  5. Jun 14, 2010Phase 2 study in Ureteral CalculiAbbVie · NCT01144949 · 239 enrolled · United States
  6. Oct 15, 2010Kissei Pharmaceutical's first study: phase 2 study in Prostatic HyperplasiaNew to Kissei PharmaceuticalKissei Pharmaceutical · NCT01222650 · 400 enrolled · Japan
  7. Oct 25, 2010JW Pharmaceutical's first studies: 2 phase 4 studiesNew to JW PharmaceuticalJW Pharmaceutical · NCT01228370, NCT01260129
  8. Dec 7, 2010Phase 4 study in Prostatic HyperplasiaJW Pharmaceutical · NCT01259531 · 100 enrolled · Korea, Republic of
  9. Feb 6, 2012Phase 4 study in UreterolithiasisJW Pharmaceutical · NCT01533389 · 114 enrolled · Korea, Republic of
  10. Feb 21, 2012Phase 2 study in Urinary CalculiKissei Pharmaceutical · NCT01539265 · 300 enrolled · Japan
  11. Dec 21, 2012Phase 4 study in Prostatic HyperplasiaRECORDATI GROUP · NCT01757769 · 1,036 enrolled · Italy
  12. Mar 31, 2014Phase 4 study in NocturiaJW Pharmaceutical · NCT02106182 · 135 enrolled · Korea, Republic of
  13. Sep 19, 2022Xintian Pharmaceutical's first study: phase 4 study in Benign Prostatic Hyperplasia With Lower Urinary Tract SymptomsNew to Xintian PharmaceuticalXintian Pharmaceutical · NCT05551221 · 110 enrolled · China
  14. Aug 14, 2025Shanghai Huilun Pharmaceutical's first study: phase 4 study in Prostatic HyperplasiaNew to Shanghai Huilun PharmaceuticalShanghai Huilun Pharmaceutical · NCT07134907 · 110 enrolled · China

TargetBeta

ADRA1A →read by rule
“Alpha-1a adrenergic receptor antagonist”ChEMBL 37, by rule

Other programs on ADRA1A

ProgramCompanyFurthest phaseStudies
TamsulosinruleBoehringer Ingelheimphase 460
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
MidodrineruleTakedaphase 410
PrazosinrulePfizerphase 34

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07134907Prostatic Hyperplasia · China4CompletedShanghai Huilun PharmaceuticalJul 9, 2024110
NCT05551221Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms · China4CompletedXintian PharmaceuticalSep 10, 2024110
NCT02106182Nocturia · Korea, Republic of4CompletedJW PharmaceuticalMar 2, 2016135
NCT01757769Prostatic Hyperplasia · Italy4CompletedRECORDATI GROUPMar 20131,036
NCT01539265Urinary Calculi · Japan2CompletedKissei Pharmaceutical300
NCT01533389Ureterolithiasis · Korea, Republic of4CompletedJW PharmaceuticalMar 2012114
NCT01259531Prostatic Hyperplasia · Korea, Republic of4CompletedJW PharmaceuticalSep 2011100
NCT01260129Prostatic Hyperplasia · Korea, Republic of4CompletedJW PharmaceuticalNov 2010424
NCT01228370Urinary Bladder, Neurogenic · Korea, Republic of4CompletedJW PharmaceuticalJan 201295
NCT01222650Prostatic Hyperplasia · Japan2CompletedKissei Pharmaceutical400
NCT01144949Ureteral Calculi · United States2CompletedAbbVieJul 2012239
NCT00793819Nocturia · United States2CompletedAbbVieOct 2009215
NCT00740779Prostatitis · United States2CompletedAbbVieOct 2009153
NCT00359905Prostatic Hyperplasia · United Kingdom3CompletedRECORDATI GROUPMay 20071,228
NCT00224133Prostatic Hyperplasia · United States3CompletedAbbVieApr 2007661
NCT00224120Prostatic Hyperplasia · United States3CompletedAbbVieMay 2006462
NCT00224107Prostatic Hyperplasia · United States3CompletedAbbVieAug 2006461

How it is read

Names in the registry

  • “Silodosin”, 12 entries
  • “silodosin”, 5 entries
  • “KSO-0400”, 2 entries
  • “Silodosin Capsules”, 1 entry
  • “Silodosin 8 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.